Physician profile
Windham Tinnell
NPI 1689442899
$2,507.51
in general payments reported to CMS, 2019-2025
28 companies · $722 in 2025
The $722 reported for 2025 was more than what 95% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $103 · 2024: $1,682 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,507.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $654.27 | 2023-2025 | Fintepla, Nayzilam, Briviact |
| Sk Life Science, INC. | $223.37 | 2023-2025 | |
| Argenx US, INC. | $175.30 | 2024-2025 | Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $164.38 | 2024-2025 | Nuplazid, Daybue |
| Astrazeneca Pharmaceuticals LP | $117.90 | 2024 | Andexxa |
| Genentech USA, INC. | $111.39 | 2024-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Neurocrine Biosciences, INC. | $91.25 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $90.48 | 2023-2024 | Hyqvia, Iclusig |
| Abbvie INC. | $80.70 | 2024 | |
| Novartis Pharmaceuticals Corporation | $71.89 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $66.03 | 2024-2025 | |
| Eisai INC. | $64.56 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $62.69 | 2023-2024 | Xeomin |
| Neurelis, INC. | $62.34 | 2024-2025 | Valtoco |
| Springworks Therapeutics, INC. | $55.78 | 2025 | Gomekli |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $51.06 | 2024 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $48.64 | 2024 | Zonisade |
| Tanabe Pharma America, INC. | $43.39 | 2024 | |
| Aucta Pharmaceuticals, INC. | $34.21 | 2025 | Motpoly Xr |
| Alnylam Pharmaceuticals INC. | $33.88 | 2024 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $33.74 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $31.96 | 2024 | Dysport |
| Immedica Pharma US, INC. | $27.00 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $25.14 | 2024 | |
| Alexion Pharmaceuticals, INC. | $22.75 | 2024 | Ultomiris |
| Amgen INC. | $22.11 | 2024 | Uplizna |
| Acorda Therapeutics, INC | $20.86 | 2024 | Inbrija |
| Emd Serono, INC. | $20.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Windham Tinnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.